Abstract 18-Amino-4Љ-O-benzoyl-4ٞ-N-demethyl-18-deoxospiramycins were designed and synthesized. Synthetic strategy involved selective demethylation of the dimethylamino group in forosamine, benzoylation of the hydroxyl group at the C4Љ position and reductive Namination of the formyl group. Antibacterial characteristics of spiramycin derivatives were tested. The derivatives exhibited promising activity against drug-resistant bacterial strains.
Introduction
Spiramycin I (1) is a 16-membered-ring macrolide with two aminosugars, mycaminose and forosamine together with one neutral sugar mycarose (Fig. 1) . It shows antibacterial activities against Gram-positive bacteria and mycoplasmas [1] . Our group has continuously studied the synthesis and biological activity of spiramycin derivatives to elucidate their structure-activity relationships [2ϳ7] . Recently, the spiramycin derivatives in our chemical library have been reinvestigated in the course of our screening for antibacterial agents. The spiramycin derivative 2a [4] , one of byproducts in the silylacetal formation, was found to show moderate activity for drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), whereas the parent compound 1 is inactive. Structurally, 2a has 3,18-(O-silyl)acetal, 4Љ-O-TBDMS and 4ٞ-methylamino groups. However, the 3,18-(O-silyl)acetal and 4Љ-O-TBDMS groups are not appropriate for medicinal uses because of their lability under acid conditions. Nevertheless, we found that the TBDMS ether 2a can be converted to esters 2b and 2c, which maintain activity against MRSA strains [8] . Moreover, acetylene compound 2c is useful for producing 1,2,3-triazole analogues via click chemistry [9] . If the remaining silylacetal moiety in 2 is converted to other functional groups without reducing activity, it could be a promising lead compound to combat drug-resistant bacteria. Herein, we report the design, synthesis and antibacterial activity of 4ٞ-Ndemethylspiramycin derivatives 3 bearing various amines instead of the 3,18-(O-silyl)acetal moiety found in 2.
Chemistry
Synthesis of spiramycin derivatives 3 is summarized in Scheme 1. Selective 2Ј-acetylation of 1 with acetic anhydride yielded 2Ј-O-acetylspiramycin 4, which was converted to 4Љ-benzoyl compound 5 in 72% yield through treatment with benzoic acid and DCC in the presence of catalytic DMAP. In this acylation step, the use of benzoic anhydride or benzoyl chloride as acylating agents gave lower yields of 5, accompanied by 3,4Љ-dibenzoyl derivative. Next, we attempted selective N-demethylation of the 4ٞ-dimethylamino group in 5 using our method previously reported [6] . However, N-demethylation with NBS and NaN 3 caused decomposition of 5. After several attempts, the reaction of 5 with FmocCl and NaHCO 3 in EtOAc under reflux smoothly proceeded to provide 4ٞ-
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Toshiaki Sunazuka, Hiroko Shudo, Kenichiro Nagai, Kiminari Yoshida, Yukie Yamaguchi, Hideaki Hanaki, Satoshi Ō mura Fmoc protected spiramycin 6 in quantitative yield via Ndemethylation of the 4ٞ-dimethylamino group without formation of 3Ј-Fmoc protected spiramycin. The selectivity of 4ٞ-N-demethylation is due to less steric hindrance around the dimethylamino group of forosamine compared to that of mycaminose. It is noted that benzoylation of the 4Љ-hydroxyl group did not work when 4 was protected with Fmoc group in advance. This result indicates that introduction of 4ٞ-N-Fmoc group causes a conformational change that forosamine is close to mycarose, and then the Fmoc group shields around 4Љ-hydroxyl group in mycarose from attack of acylating agents. The formyl group of 6 was treated with a variety of amines in the presence of NaBH(OAc) 3 and AcOH to afford amine compounds 7 in high yields [10] . Finally, deprotection of the Fmoc group with piperidine, followed by methanolysis of the acetyl group provided spiramycin derivatives 3 in good yields. DBU can be used for deprotection of the Fmoc group without decomposition of the spiramycin skeleton.
Results and Discussion
The in vitro antibacterial activities of spiramycin derivatives 3 were tested by the standard agar dilution method against S. aureus FDA209P (susceptible strain), S. aureus Smith (susceptible strain), MRSA HH-1 (methicillin-resistant S. aureus), MRSA HH-1 HR-1 (methicillin-resistant S. aureus), MRSA 70 (methicillinresistant S. aureus), MRSA 92-1191 (methicillin-resistant S. aureus), S. aureus ISP447 (inducibly resistant strain), S. aureus ISP217 (constitutively resistant strain), S. aureus 8325 (pEP2104) (encoded by erm gene), S. aureus 8325 (pMS97) (encoded by erm and mef genes) shown in Table  1 .
Spiramycin I (1) displayed anitibacterial activity against S. aureus FDA209P and S. aureus Smith with an MIC value of 2.0 and 4.0 mg/ml respectively, but no activity for MRSA strains. Dibenzylamino spiramycin 3a was less active against EM susceptible strains compared to 1, while 3a showed antibacterial activity against MRSA strains with MIC values of 8.0~16 m g/ml. However, 3a showed weak activity compared to vancomycin. Compound 3b was slightly less active than 3a. These results indicate that the replacement of the 3,18-(O-silyl)acetal moiety in 2a and 2b with a suitable amino group at C18 does not reduce activity significantly. Exceptionally, monobenzylamino spiramycin 3c lost activity against all tested strains. The phenyl group seems to have a crucial effect on antibacterial activity because pyridine derivatives 3d and 3e were inactive against all susceptible and resistant strains. The significance of the position and orientation of the phenyl group is emphasized because 3c and 3f having the phenyl group showed no activity. Furthermore, indoline 3g and tetrahydroquinoline 3i displayed moderate activity against MRSA strains, whereas isoindoline 3h and tetrahydroisoquinoline 3j diminished activity against all tested strains. To examine the effect of the three functional groups in 3g on anti-MRSA activity, spiramycin derivatives 8, 9 and 10 were prepared (Fig. 2) . Surprisingly, 8, 9 and 10 showed no antibacterial activity, suggesting that combination of the 18-N-indolino, 4Љ-O-benzoyl and 4ٞ-Nmethylamino groups bestows effectiveness against drugresistant strains.
Conclusion
In conclusion, we have demonstrated the synthesis and antibacterial activity of 18-amino-4Љ-O-benzoyl-4ٞ-Ndemethyl-18-deoxospiramycins. The structural features of the potent compound, 3g include the 18-N-indolino, 4Љ-Obenzoyl and 4ٞ-N-methylamino groups. Although 3a, 3b, 3g and 3i are less potent than vancomycin (MIC: MRSA strains; 0.5ϳ1.0 m g/ml), this result may offer useful information to help design 16-membered-ring macrolide derivatives with effectiveness against drug-resistant strains. Based on these results, further spiramycin derivatives are being investigated. The in vivo biological activity will be reported elsewhere. 
Experimental
Reagents were purchased at highest commercial quality and used without further purification, unless specified otherwise. Reactions were monitored by TLC using Merck F60 254 silica gel plates. The plates were visualized with UV light and stained with phosphomolybdic acid. Silica gel chromatography was performed on Merck Kieselgel 60 (Art. 1.09385).
FT-IR spectra were recorded on a Horiba FT-210 spectrometer. Mass spectra were recorded on a JEOL JMS-AX505 HA Mass Spectrometer.
1 H-NMR spectra were recorded on a JEOL JNM-EX270 spectrometer in CDCl 3 , CD 3 OD or pyridine-d 5 .
1 H-NMR spectral data are reported as follows: chemical shifts relative to chloroform (7.26 ppm), multiplicity (sϭsinglet, dϭdoublet, tϭtriplet, qϭquartet, mϭmultiplet, brϭbroad), coupling and integration.
2-O-Acetylspiramycin I (4)
To a solution of spiramycin I (1) (6.70 g, 7.95 mmol) in Me 2 CO (9.9 ml) was added acetic anhydride (2.25 ml, 23.8 mmol), and the mixture was stirred at room temperature. After stirring for 5 hours, the solvent was concentrated under reduced pressure. The residue was diluted with CHCl 3 and washed with saturated aq NaHCO 3 and H 2 O. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and evaporated to give 4 (7.03 g, quant.) as a colorless powder.
HR (dd, Jϭ14.9, 9.7 Hz, 1H, H-12), 5.61 (dd, Jϭ15.1, 9. Acetyl-4؆-O-benzoyl-4ٟ-N-demethyl-4ٟ-N-(9-fluorenylmethoxycarbonyl) spiramycin I (6) To a solution of 5 (3.13 g, 3.17 mmol) in EtOAc (32 ml) were added NaHCO 3 (1.34 g, 17.0 mmol) and 9-fluorenylmethylchloroformate (2.85 g, 11.0 mmol), and the mixture was stirred under reflux. After stirring for 3.5 hours, the mixture was cooled to room temperature. The mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na 2 SO 4 , filtered and evaporated. The residue was purified by column chromatography on silica gel with an eluent (hexane : 
2-O-
EtOAcϭ3 : 1 to 1 : 1) to give 6 (3.80 g, quant.) as a colorless powder
2-O-Acetyl-4؆-O-benzoyl-4ٟ-N-demethyl-18-(N,Ndibenzyl)amino-4ٟ-N-(9-fluorenylmethoxycarbonyl)-18-deoxospiramycin I (7a)
To a solution of 6 (78.5 mg, 65.6 mmol) in CHCl 3 (656 ml) were added N,N-dibenzylamine (19.0 m l, 98.4 m mol) and AcOH (9.40 ml, 164 mmol), and the mixture was stirred at room temperature for 15 minutes. Then NaHB(OAc) 3 
2-O-Acetyl-4؆-O-benzoyl-4ٟ-N-demethyl-18-(N,Ndibenzyl)amino-18-deoxospiramycin I
To a solution of 7a (70.8 mg, 51.4 mmol) in EtOAc (514 ml) was added piperidine (5.60 ml, 56.5 mmol) and the mixture was stirred at room temperature. After stirring for 6 hours, the mixture was diluted with a 1 : 1 mixture of EtOAc and hexane, washed with saturated aq NaHCO 3 and brine, dried over anhydrous Na 2 SO 4 , filtered and evaporated. The residue was purified by column chromatography on silica gel with an eluent (CHCl 3 Benzoyl-4ٟ-N-demethyl-18-(N,N-dibenzyl) -4ٟ-N-demethyl-18-(N,N-di-3 -4ٟ-N-demethyl-18-(indolin-1-yl) , 1H, H-1Ј), 4.19 (m, 1H, H-5 Benzoyl-4ٟ-N-demethyl-18-(isoindolin-2-yl) -4ٟ-N-demethyl-18-(1,2,3,4-tetrahydroquinolin-1-yl) -4ٟ-N-demethyl-18-(1,2,3,4-tetrahydroisoquinolin-2-yl)-18-deoxospiramycin I (3j 
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4؆-O-Benzoyl-18-(indolin-1-yl)-18-deoxospiramycin I (9)
Title compound 9 was prepared from compound 5 by Namination followed by methanolysis (84%, 2 steps). (FAB) (matrix; m-NBA 
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